Clinical trials: Sjögren's Disease
Sjogren's Syndrome
EVADRY® in the Treatment of Xerostomia in Sjögren's Syndrome
Xerostomia is a common and very bothersome manifestation that impairs the quality of life in Sjogren's syndrome. Symptomatic therapeutic alternatives for this syndrome are limited in Tunisia.
- Trial name
- DRYLESS (NCT06313905)
- Testing
- EVADRY
- Volunteers
- 180 people
- Sponsor
- University Tunis El Manar
Sjogren's Syndrome
Sjogren's Mini-Pill Oral and Gut Microbiome Study
The goal of this observational study is to characterize and compare region-specific gastrointestinal, stool, oral, and periodontal microbiomes in adults with Sjögren's disease and healthy controls using ingestible mini-pill…
- Trial name
- NCT07732582
- Testing
- Mini-Pill
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Tufts University
Sjogren Syndrome, Sjogren Disease
TREATMENT OF VAGINAL DRYNESS IN SJÖGREN'S DISEASE WITH CO2-LASER VERSUS TOPICAL PROMESTRIENE
Sjögren's disease (SjD) is a chronic, immune-mediated, systemic inflammatory disease characterized mainly by involvement of the salivary and lacrimal glands, causing symptoms of sicca syndrome.
- Conditions
- Sjogren Syndrome, Sjogren Disease, Primary Sjogren Syndrome
- Trial name
- VaLS (NCT07153276)
- Testing
- Fractional CO2 laser (vaginal), Promestriene Vaginal
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo General Hospital
Dry Eye Disease
Efficacy of 0.05% Cyclosporine A Eye Drops Combined With Absorbable Tear Duct Plugs in the Treatment of Dry Eye in Sjögren's Syndrom
To study the effectiveness of 0.05% cyclosporine A eye drops in combination with smart plug absorbable lacrimal duct plugs in the monotherapy of cyclosporine for SSDE.
- Trial name
- NCT07171710
- Testing
- 0.05% Cyclosporine Eye Drops, Smart plug absorbable lacrimal duct plugs
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Eye Hospital
Sjogren's Syndrome
Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome
The ANISE-II study is a randomized, double-blind, placebo-controlled phase IIa proof-of-concept trial. Thirty patients with primary Sjögren's syndrome (pSS) are randomized in a 2:1 ratio to either anifrolumab or placebo treatment…
- Trial name
- ANISE-II (NCT05383677)
- Testing
- Anifrolumab
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- University Medical Center Groningen
Primary sjögren's Syndrome
Ultrasound Abnormalities of the Salivary Glands in Primary Sjögren's Syndrome According to the Duration of the Disease
Salivary gland ultrasonography is identified as a valuable diagnostic tool and potential criteria item for disease classification of sjögren's syndrome and evaluate evolution of parenchyma.
- Trial name
- MASAÏ (NCT04212572)
- Where
- 3 sites in France
- Volunteers
- 242 people
- Sponsor
- University Hospital, Brest
Healthy, Idiopathic Inflammatory Myopathies
A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
The purpose of this study is to determine the safety and tolerability of XmAb657 in healthy participants and participants with autoimmune diseases.
- Conditions
- Healthy, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjögren's Disease
- Trial name
- NCT07284797
- Testing
- XmAb657
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Xencor, Inc.
Sjogren's Syndrome
Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome
This study will evaluate the safety and tolerability of iscalimab at two dose levels in patients with Sjögren's Syndrome, who participated in the TWINSS core study, CCFZ533B2201 (NCT03905525).
- Trial name
- TWINSS Extn (NCT04541589)
- Testing
- Iscalimab
- Where
- 62 sites in United States, Argentina and 21 more
- Volunteers
- 206 people
- Sponsor
- Novartis Pharmaceuticals
Primary Sjögren's Syndrome
The ASSESS National Multi-center Prospective Cohort
The ASSESS national multi-center prospective cohort (Assessment of Systemic complications (Signs) and Evolution in Sjögren's Syndrome "SS") was set up in 2006 thanks to a grant of the French Ministry of Health.
- Trial name
- ASSESS (NCT03040583)
- Testing
- No intervention
- Where
- France
- Volunteers
- 395 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sjögren's Disease
A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of IBI355 in participants with moderate-to-severe Sj?gren's disease (SjD).
- Trial name
- NCT07836660
- Testing
- Part B -Telitacicept, Part A - IBI355
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Sjogren Syndrome
Fatigue in Sjögren's Syndrome: 3 Therapeutic Strategies
Unexplained fatigue is a frequent (60-70%) chronic complaint in Sjögren's syndrome (SjS) with a clear unmet therapeutic need, despite the recommendation of adapted physical activity (APA) programs, which are effective and…
- Trial name
- FESSONA (NCT06875102)
- Testing
- Acupuncture (ACU), Transcutaneous Vagus Nerve Stimulation (tVNS), APA (adapted physical activity )
- Where
- France
- Volunteers
- 174 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Sjogren's Syndrome
Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome
This study is a multi-national, multi-center, double-blind (sponsor open), randomized, placebo-controlled trial in subjects with active primary Sjögren's syndrome designed to understand the safety and tolerability profile of…
- Trial name
- NCT02631538
- Testing
- Belimumab, Rituximab
- Where
- 36 sites in Argentina, Canada and 8 more
- Volunteers
- 86 people
- Sponsor
- GlaxoSmithKline
Sjögren's Disease
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
To evaluate efficacy, safety, and tolerability of DDY391 up to 52 weeks in participants with Sjögren's disease (SjD) and to determine the dose response relationship of DDY391 in participants with SjD, to support dose selection…
- Trial name
- NCT07737743
- Testing
- DDY391
- Where
- 25 sites in United States, Australia and 4 more
- Volunteers
- 344 people
- Sponsor
- Novartis Pharmaceuticals
Primary Sjogren's Syndrome, Secondary Sjogren's Syndrome
Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study
The primary purpose of this pilot study is to evaluate the efficacy and safety of Abatacept in subjects with Sjogren's Syndrome (SS).
- Conditions
- Primary Sjogren's Syndrome, Secondary Sjogren's Syndrome, Inflammatory Arthritis, Rheumatoid Arthritis
- Trial name
- NCT02027298
- Testing
- Abatacept
- Where
- United States
- Sponsor
- The Cleveland Clinic
Sjogren's Syndrome, Fatigue
Fatigue in Primary Sjögren's Syndrome
Fatigue is a common clinical finding in Primary Sjögren's syndrome (PSS). In PSS, there is not enough data about the conditions in which fatigue develops and which clinical conditions the disease is associated with.
- Conditions
- Sjogren's Syndrome, Fatigue, Pain Syndrome, Depression
- Trial name
- NCT04802577
- Testing
- FACT-F questionnaire, Beck Depression Inventory, Beck Anxiety Inventory
- Where
- Turkey (Türkiye)
- Volunteers
- 110 people
- Sponsor
- Bursa Yuksek Ihtisas Training and Research Hospital
Sjögren's Syndrome
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
The primary objective of this study is to evaluate the efficacy of treatment with either lulizumab or BMS-986142 versus placebo in subjects with moderate to severe primary Sjögren's syndrome as measured by the change from…
- Trial name
- NCT02843659
- Testing
- BMS-931699, BMS-986142
- Where
- 34 sites in United States, Australia and 9 more
- Volunteers
- 45 people
- Sponsor
- Bristol-Myers Squibb
Primary Sjögren's Syndrome
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
This study did evaluate the safety,tolerability and preliminary therapeutic efficacy of multiple doses of intravenous infusion of CFZ533 monoclonal antibody in patients with primary Sjögren's syndrome(pSS)
- Trial name
- NCT02291029
- Testing
- CFZ533 active - Cohort 1, CFZ533 active - Cohort 2, CFZ533 active -Cohort 3
- Where
- 9 sites in United States, Germany and 3 more
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
Sjogren's Syndrome
Comprehensive Evaluation of Clinical and Biopsychosocial Characteristics in Primary Sjögren's Disease
Following the guidance of individuals with primary Sjögren's Syndrome who receive diagnosis, routine medical care, and treatment management, the evaluations will be performed once by the researchers and will take approximately…
- Trial name
- NCT06410742
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Kahramanmaras Sutcu Imam University
Sjögren's Syndrome, Rheumatic Diseases
Impact of Korean Red Ginseng on Fatigue in Patients With Rheumatic Disease
The objective of a randomized, double-blind, placebo-controlled trial and open-label extension study is to figure out the impact of Korean Red Ginseng (KRG) on fatigue in patients with rheumatic diseases.
- Conditions
- Sjögren's Syndrome, Rheumatic Diseases, Korean Red Ginseng
- Trial name
- NCT03983408
- Testing
- Korean Red Ginseng
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Hanyang University
Sjögren's Syndrome, Small Fiber Neuropathy
Evaluation of the Prevalence, and Immunological Characteristics of Small Fiber Neuropathy in Patients With Primary Sjögren's Syndrome
The investigators propose to conduct a prospective study evaluating the prevalence of SNN in pSS patients and to find clinical characteristics and specific immunological profiles in pSS patients with SFN.
- Conditions
- Sjögren's Syndrome, Small Fiber Neuropathy, Autonomic Dysfunction, Autoantibodies
- Trial name
- NEUROSS (NCT07917442)
- Testing
- Sudoscan testing
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens